Reaction

Shoulder Fracture reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,537 reports · 39 co-occurring drugs

As of the last recalculation, Shoulder Fracture appears in 1,537 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is EMTRICITABINE AND TENOFOVIR ALAFENAMIDE (PRR 20.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Emtricitabine And Tenofovir Alafenamide	17	20.5	20.5
Human Immunoglobulin G	30	20.1	20.1
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	24	18.2	18.2
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	11	16.7	16.7
Risankizumab-Rzaa	87	15.2	15.2
Calcium, Magnesium, Potassium, And Sodium Oxybates	9	14.2	14.2
Abaloparatide	30	14.1	14.1
Upadacitinib	77	13.4	13.4
Crisaborole	9	12.8	12.8
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	9	12.2	12.2
Dolutegravir Sodium	8	12.1	12.1
Vibegron	7	11.9	11.9
Cenobamate	7	11.4	11.4
Linagliptin	14	10.5	10.5
Eptinezumab-Jjmr	7	10.5	10.5
Alendronate Sodium Tablet	14	10.3	10.3
Acalabrutinib	9	10.1	10.1
Emtricitabine And Tenofovir Disoproxil Fumarate	33	10.0	10.0
Romosozumab-Aqqg	9	9.0	9.0
Insulin Degludec	15	8.7	8.7
Tenofovir Disoproxil Fumarate	20	8.3	8.3
Benzonatate	10	8.2	8.2
Diroximel Fumarate	7	8.0	8.0
Brivaracetam	5	7.6	7.6
Benralizumab	11	7.5	7.5
Rifaximin	10	6.5	6.5
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	6.5	6.5
Desoximetasone	9	6.4	6.4
Ravulizumab	6	6.0	6.0
Olaparib	9	5.9	5.9
Vedolizumab	35	5.6	5.6
Inclisiran	3	5.1	5.1
Oral Semaglutide	26	4.9	4.9
Ocrelizumab	22	4.9	4.9
Osimertinib	11	4.7	4.7
Tafamidis	4	4.6	4.6
Guselkumab	12	4.6	4.6
Pimavanserin Tartrate	18	4.4	4.4
Bimekizumab	5	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.